Literature DB >> 26464215

Dependency of Experimental Autoimmune Encephalomyelitis Induction on MOG35-55 Properties Modulating Matrix Metalloproteinase-9 and Interleukin-6.

Ji-Eun Seo1,2,3, Mahbub Hasan1,2,3, Joon-Seung Han1,2, Nak-Kyoon Kim4, Ji Eun Lee5, Kang Mi Lee2, Ju-Hyung Park2, Ho Jun Kim2, Junghyun Son2, Jaeick Lee2, Oh-Seung Kwon6,7,8.   

Abstract

Experimental autoimmune encephalomyelitis (EAE) is commonly induced with myelin oligodendrocyte glycoprotein (MOG)35-55; occasionally, EAE is not well induced despite MOG35-55 immunization. To confirm that EAE induction varies with difference in MOG35-55 properties, we compared three MOG35-55 from different commercial sources, which are MOG-A, MOG-B, and MOG-C. The peptides induced EAE disease with 100, 40, and 20 % incidence, respectively. Compared with others, MOG-A showed higher peptide purity (99.2 %) and content (92.2 %) and presented a sheet shape with additional sodium and chloride chemical elements. In MOG-A-treated group, MMP-9 activity and IL-6 levels were considerably higher than the other groups in CNS tissues, and significantly increased VCAM-1, IFN-γ, and decreased IL-4 were also shown compared to MOG-B- and/or MOG-C-treated group. In conclusion, the immunological and toxicological changes by the difference in MOG35-55 properties modulate EAE induction, and MOG35-55 which affects MMP-9 activity and IL-6 levels may be the most effective EAE-inducing antigen. This study can be potentially applied by researchers using MOG35-55 peptide and manufacturers for MOG35-55 synthesis.

Entities:  

Keywords:  EAE; IL-6; Induction; MMP-9; MOG35-55; Property

Mesh:

Substances:

Year:  2015        PMID: 26464215     DOI: 10.1007/s11064-015-1732-9

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  34 in total

Review 1.  Blood-brain barrier disruption in multiple sclerosis.

Authors:  Alireza Minagar; J Steven Alexander
Journal:  Mult Scler       Date:  2003-12       Impact factor: 6.312

Review 2.  Metalloproteinases: mediators of pathology and regeneration in the CNS.

Authors:  V Wee Yong
Journal:  Nat Rev Neurosci       Date:  2005-12       Impact factor: 34.870

3.  Focal MMP-2 and MMP-9 activity at the blood-brain barrier promotes chemokine-induced leukocyte migration.

Authors:  Jian Song; Chuan Wu; Eva Korpos; Xueli Zhang; Smriti M Agrawal; Ying Wang; Cornelius Faber; Michael Schäfers; Heinrich Körner; Ghislain Opdenakker; Rupert Hallmann; Lydia Sorokin
Journal:  Cell Rep       Date:  2015-02-19       Impact factor: 9.423

4.  Acute toxicity and tissue distribution of CdSe/CdS-MPA quantum dots after repeated intraperitoneal injection to mice.

Authors:  Md Mamunul Haque; Hye-Yeon Im; Ji-Eun Seo; Mahbub Hasan; Kyoungja Woo; Oh-Seung Kwon
Journal:  J Appl Toxicol       Date:  2012-06-25       Impact factor: 3.446

Review 5.  T cells in multiple sclerosis and experimental autoimmune encephalomyelitis.

Authors:  J M Fletcher; S J Lalor; C M Sweeney; N Tubridy; K H G Mills
Journal:  Clin Exp Immunol       Date:  2010-10       Impact factor: 4.330

Review 6.  Th17 cell, the new player of neuroinflammatory process in multiple sclerosis.

Authors:  F Jadidi-Niaragh; A Mirshafiey
Journal:  Scand J Immunol       Date:  2011-07       Impact factor: 3.487

Review 7.  Autoimmune T cell responses in the central nervous system.

Authors:  Joan Goverman
Journal:  Nat Rev Immunol       Date:  2009-06       Impact factor: 53.106

8.  IL-5-deficient mice are susceptible to experimental autoimmune encephalomyelitis.

Authors:  Catherine Weir; Claude C A Bernard; B Thomas Bäckström
Journal:  Int Immunol       Date:  2003-11       Impact factor: 4.823

9.  P2x7 deficiency suppresses development of experimental autoimmune encephalomyelitis.

Authors:  Anthony J Sharp; Paul E Polak; Vittoria Simonini; Shao X Lin; Jill C Richardson; Ernesto R Bongarzone; Douglas L Feinstein
Journal:  J Neuroinflammation       Date:  2008-08-08       Impact factor: 8.322

10.  Animal models of multiple sclerosis: the good, the bad and the bottom line.

Authors:  Richard M Ransohoff
Journal:  Nat Neurosci       Date:  2012-07-26       Impact factor: 24.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.